Jaguar Health Inc (NQ: JAGX )
0.1831 -0.0821 (-30.96%) Streaming Delayed Price Updated: 4:00 PM EST, Dec 11, 2023 Add to My Watchlist
All News about Jaguar Health Inc
Italian Government Clears Merger Plan of Dragon SPAC S.p.A. and Jaguar Health's Italian Subsidiary Napo EU S.p.A. for Closing
October 25, 2021
Merger expected to be effective within a week The combined entity will be named Napo EU S.p.A. Merger effects the exclusive license agreement between Jaguar and Napo EU S.p.A. including up-front...
Jaguar Health Provides Updates on Crofelemer and Lechlemer Development Pipeline as well as Merger of Napo EU S.p.A. and Dragon SPAC S.p.A.
October 07, 2021
Dragon SPAC and Jaguar subsidiary Napo EU submit required notification to the Italian government in support of consummating the merger Results accepted for third-party, investigator-initiated Phase 2...
Jaguar Health's Founder and CEO Lisa Conte to Be Honored with Pure Earth Impact Award
September 30, 2021
Award celebrates Ms. Conte's 30-year, unrelenting commitment to supporting Indigenous communities in the Amazon and responsibly harvesting and commercializing the first-ever plant-based oral medicine...
Jaguar Health Announces that Ladenburg Thalmann is Hosting R&D Showcase Webinar About Cancer Therapy-related Diarrhea on September 29, 2021
September 27, 2021
Leading oncologists discuss importance of supportive care for cancer patients to address debilitating diarrhea resulting from cancer therapy Virtual event 1:00 PM to 2:10 PM Eastern Registration open...
Jaguar Health Receives "Complete" Letter from FDA for Last of Four Major Technical Sections for the Company's Application for Conditional Approval of Canalevia (Crofelemer) for Chemotherapy-Induced Diarrhea (CID) in Dogs
September 23, 2021
Jaguar planning for launch of Canalevia™ for CID in dogs this December Canalevia is the first and only oral plant-based prescription drug candidate for CID in dogs SAN FRANCISCO, CA / ACCESSWIRE /...
REMINDER: Jaguar Health to Host Investor Webcast Monday, September 20th at 8:30 AM Eastern Time
September 16, 2021
Click here to register for webcast Jaguar kicks off educational awareness contest in honor of Indigenous Peoples' Day; Click here to enter SAN FRANCISCO, CA / ACCESSWIRE / September 16, 2021 / Jaguar...
Orphan Drug Designation Application Submitted by Jaguar Health Subsidiary for Crofelemer for Short Bowel Syndrome with Intestinal Failure Accepted for Review by European Medicines Agency
September 15, 2021
The conditional marketing authorization pathway in Europe for crofelemer for this orphan disease is the initial focus of Napo EU under the license agreement between Napo EU and Napo Pharmaceuticals...
Jaguar Health Announces Closing of Private Placement Priced at a Premium to Market
September 14, 2021
Participating investors include Jaguar CEO and CFO, Dragon SPAC S.p.A. sponsor Josh Mailman, and plant-based pharmaceutical manufacturing pioneer Indena S.p.A. Company to host investor webcast Monday,...
Jaguar Health Appoints Karen Brunke, Ph.D. as Corporate and Business Development EVP and Chip Whitlow as Animal Health Products Marketing Director
September 09, 2021
Appointments represent Jaguar's focus on forging business development partnerships to advance crofelemer development and access and preparing for the expected near-term approval and commercialization...
Jaguar Health, Inc. Announces 1-for-3 Reverse Stock Split
September 03, 2021
- Reverse split approved by majority of common stock shareholders at December 2020 special meeting of stockholders - Shares of Jaguar common stock to begin trading on split-adjusted basis on September...
Proposals 1, 2, 4, 5 & 6 approved SAN FRANCISCO, CA / ACCESSWIRE / September 3, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's...
Jaguar Health Subsidiary Napo Pharmaceuticals Submits Late-Breaking Abstract for Consideration for Presentation at the 2021 IDWeek Annual Meeting
August 23, 2021
Exploratory study evaluating effects of crofelemer on gut microbiome SAN FRANCISCO, CA / ACCESSWIRE / August 23, 2021 / Napo Pharmaceuticals, the wholly-owned subsidiary of Jaguar Health, Inc....
Jaguar Health Subsidiary Napo Pharmaceuticals Signs License Agreement with its Italian Subsidiary, Napo EU S.p.A., to Develop and Commercialize Crofelemer and Lechlemer in Europe
August 19, 2021
Per the terms of the agreement, Napo Pharmaceuticals will receive an upfront payment of $10 million payable in two installments following the anticipated merger of Napo EU and Dragon SPAC S.p.A. and is...
Jaguar Health Subsidiary Announces Completion of Additional Preclinical Study of Lechlemer (NP-300), the Company's Human Drug Product Candidate for Diarrhea Relief from Cholera and Other Acute Infectious Diarrhea
August 17, 2021
In support of planned Investigational New Drug application for lechlemer, Napo Pharmaceuticals, Jaguar's wholly owned subsidiary, received comprehensive animal toxicity preclinical services supported...
Second quarter 2021 Mytesi® net and gross sales were approximately $0.4 million and approximately $4.9 million Company transitioning to primarily selling Mytesi directly through selected specialty...